Cardiac Regeneration Drug Pipeline — PatSnap Eureka
Cardiac Regeneration Drug Pipeline: Cardiomyocyte Proliferation, Hippo Pathway & mRNA Approaches
Cardiovascular disease remains the leading cause of death worldwide. A rapidly diversifying pipeline—spanning ncRNA modulation, Hippo/YAP targeting, modified mRNA delivery, and small molecule cell cycle activators—is emerging to restore contractile myocardium after irreversible cardiomyocyte loss.
Research Volume by Therapeutic Modality
Papers retrieved per approach, 2008–2023 dataset
Why Cardiomyocyte Proliferation Is the Central Therapeutic Goal
Retrieved results consistently identify the irreversible loss of cardiomyocytes (CMs) following myocardial infarction as the central pathological event driving progression to heart failure. Adult mammalian CMs exit the cell cycle perinatally and enter a postmitotic state that prevents meaningful endogenous regeneration — a finding unanimously recognised across more than 30 retrieved papers spanning 2008–2023.
A critical developmental window has reframed the field's strategy: neonatal mouse and pig hearts retain robust regenerative capacity via CM proliferation from pre-existing CMs, a capacity lost within days to weeks postnatally. Rather than supplying exogenous cells, the goal is now to reactivate developmental proliferative programs in existing CMs. This shift is documented in sources from the PatSnap life sciences intelligence platform and academic institutions including the University of Edinburgh (2018) and NorthStar Genomics (2023).
The WHO identifies cardiovascular disease as the leading cause of death globally, underscoring the unmet clinical need that this pipeline addresses. Key molecular targets span YAP/Hippo pathway components, cell cycle regulators (cyclins D1, D2, T1; CDK inhibitors p21/p27), non-coding RNAs, the NRG1/ErbB2/ErbB4 signaling axis, and metabolic regulators including mTOR and the PI3K/AKT/PTEN axis.
The PatSnap analytics platform enables R&D teams to map these target landscapes and identify white-space opportunities across the cardiac regeneration pipeline. Explore the full dataset with PatSnap Eureka.
Six Approaches Driving the Cardiac Regeneration Pipeline
From non-coding RNA mimics to modified mRNA and small molecule cell cycle activators, the pipeline spans mechanistically distinct but convergent strategies to restore contractile myocardium.
Non-Coding RNA Modulation (miRNA, lncRNA, circRNA)
Specific ncRNAs act as post-transcriptional switches governing CM cell cycle entry or arrest. Pro-proliferative miRNAs include miR-590, miR-199a, miR-17-92 cluster, miR-302-367 cluster, and miR-222. The miR-106b~25 cluster orchestrates the transition from CM hyperplasia to hypertrophy by targeting E2f5, Cdkn1c, Ccne1, and Wee1. AAV9-mediated delivery of miR-301a promotes G1/S transition via the PTEN/PI3K/AKT axis in mouse MI models.
lncRNA Snhg1 → c-Myc/PI3K-AKT loopHippo/YAP Pathway Targeting
The Hippo pathway operates through MST1/2 and LATS1/2 kinases that phosphorylate and inactivate YAP. When Hippo signaling is suppressed, YAP enters the nucleus and drives pro-proliferative gene programs. The small molecule TT-10 activates YAP/TEAD in CMs in vivo, reducing post-MI cardiac dysfunction in mice via clonal expansion of existing CMs (Kansai Medical University, 2018). Independent convergence from MD Anderson, UT Southwestern, and Kansai Medical University validates this axis.
TT-10 → YAP/TEAD activation in vivoModified mRNA (modRNA) Approaches
Two distinct modRNA strategies have been identified. Myc-Ccnt1 modRNA (University of Queensland, 2023): a single dose of modified mRNA encoding the Myc-Ccnt1 fusion drives CM proliferation in human iPSC-derived CMs and improves long-term cardiac function in a mouse MI model. FSTL1 modRNA (Icahn School of Medicine at Mount Sinai, 2018): a glycosylation-site mutant (N180Q) induces CM proliferation, exploiting the fact that bacterially synthesised FSTL1 (lacking mammalian glycosylation) is proliferative while mammalian-produced FSTL1 is not.
Non-integrating · no genomic modificationSmall Molecule Cell Cycle Activators
CHIR99021 (GSK-3β inhibitor) promotes CM proliferation in human iPSC-derived CMs in 3D collagen microtissues (Friedrich-Alexander University, 2021). The CHIR99021 + A-485 combination generates regenerative cardiac cells from hESC-derived CMs with capacity to differentiate into CMs, endothelial cells, and smooth muscle cells (Tsinghua University, 2023). Cyclin D2 overexpression in postnatal mouse hearts produced a more than 500-fold increase in cell cycle activity and infarct regression (Indiana University, 2009).
Cyclin D2 → >500× cell cycle activityGrowth Factor–Based Approaches (NRG1/ErbB, FGF10)
NRG1/ErbB2/ErbB4 is a mitogenic signal for CMs. In zebrafish, injury-induced Nrg1 in perivascular cells drives CM hyperplasia, epicardial activation, and increased vascularization (Duke University, 2015). Single-cell RNA sequencing in regenerating zebrafish hearts shows proliferating border zone CMs have reduced mitochondrial gene expression and increased glycolysis — metabolic reprogramming dependent on ErbB2 signaling (Vrije Universiteit Amsterdam, 2019). NRG1's efficacy in adult mammalian CMs remains contested.
ErbB2 → glycolytic shift in proliferating CMsDirect Cardiac Reprogramming
Cardiac fibroblasts constitute more than 50% of cardiac cells. Direct reprogramming converts them to CM-like cells in situ, simultaneously reducing scar and increasing functional CM mass. Transcription factor cocktails (Gata4, Mef2c, Tbx5; with Hand2), miRNA combinations, and small molecules have all been employed. OSKM-mediated reversible reprogramming (University of North Carolina, 2022) suggests that transiently reverting adult CM identity to an immature proliferative state may be a distinct and powerful strategy.
Fibroblasts >50% of cardiac cellsKey Molecular Targets & Research Signals
Quantitative signals from 30+ retrieved papers spanning 2008–2023, synthesised via PatSnap Eureka patent and literature analysis.
Proliferation Signal Magnitude by Intervention
Reported fold-change in cardiomyocyte cell cycle activity or new CM generation across key retrieved interventions.
Assignee Geography: Institutional Research Activity
Distribution of retrieved paper-producing institutions by region, reflecting the global academic landscape in cardiac regeneration research.
Core Signaling Axes Governing Cardiomyocyte Fate
Convergent evidence from independent research groups positions these axes as the proximal effectors of CM cell cycle re-entry.
YAP / Hippo Kinase Cascade
YAP is the primary transcriptional effector of CM proliferative capacity. Upstream Hippo kinases (MST1/2, LATS1/2) phosphorylate YAP, sequestering it in the cytoplasm. TT-10 demonstrates that pharmacological YAP/TEAD activation in vivo improves post-MI function in mice. Myoglobin's oxidative regulation of Hippo kinases provides a novel endogenous linkage between metabolic state and CM fate. Independent convergence from MD Anderson, Kansai Medical University, and UT Southwestern validates this axis as a high-conviction target.
c-Myc / PI3K-AKT / PTEN Axis
lncRNA Snhg1 activates this cascade by directly binding PTEN (confirmed by RNA pull-down assays), leading to PI3K-AKT pathway activation and c-Myc upregulation in a positive feedback loop with confirmed in vivo effects in MI mouse models including CRISPR/Cas9-generated CM-specific knockout mice (Nanfang Hospital, Southern Medical University, 2020–2021). The Myc-Ccnt1 modRNA approach directly engages this transcriptional program. miR-301a also operates through PTEN suppression to activate PI3K/AKT-driven G1/S transition.
Combination Strategies: The Likely Path to Clinical Efficacy
No single retrieved approach produces complete cardiac regeneration. Convergent signals point to multi-modal product designs as the future of this pipeline.
modRNA + Pro-Proliferative Transcription Factors
The Myc-Ccnt1 modRNA approach (University of Queensland, 2023) signals that transient, non-integrating mRNA encoding combinatorial transcription factor cargo can drive meaningful CM proliferation with functional recovery. Single nuclei sequencing was used to characterise the proliferating population, demonstrating increasing integration of multi-omics as a validation strategy. The non-integrating nature is explicitly cited as a translational advantage analogous to the precedent established by mRNA vaccines.
Non-integrating · human iPSC validationSmall Molecule Combinations: Wnt + Epigenetic Regulators
The CHIR99021 (GSK-3β/Wnt activator) + A-485 (CBP/p300 inhibitor) combination identified at Tsinghua University (2023) generates regenerative cardiac cells from hESC-derived TNNT2+ CMs with capacity to differentiate into CMs, endothelial cells, and smooth muscle cells. This suggests combinatorial epigenetic and signaling interventions may unlock CM plasticity more effectively than single agents. Data on this approach is accessible via PatSnap analytics.
RCC generation · tri-lineage potentialHippo Pathway + Metabolic Reprogramming
Retrieved results from University of Washington (mTOR/glutamine), Vrije Universiteit Amsterdam (ErbB2/glycolysis), and the Hippo/myoglobin paper collectively suggest that metabolic reprogramming (glycolytic shift, amino acid sensing via mTOR) and Hippo pathway suppression are mechanistically linked. These pathways may need to be co-targeted for efficient proliferation induction, representing a mechanistically grounded but underexploited therapeutic space in the post-MI border zone.
mTOR + YAP co-targeting hypothesisNOTCH1 Inhibition + Direct CM Proliferation
Signals from University of Lausanne (2022) suggest NOTCH1 inhibition may serve as a complementary strategy to reduce fibrosis and simultaneously promote non-myocyte conversion into the cardiomyocyte fate, potentially acting synergistically with direct CM proliferation strategies. OSKM-mediated reversible reprogramming (University of North Carolina, 2022) suggests that transiently reverting adult CM identity to an immature proliferative state may bridge reprogramming and cell cycle re-entry approaches. See the PatSnap customer stories for how pharma teams use these signals.
Anti-fibrotic · pro-cardiogenic synergyPipeline Translation Status by Modality
A snapshot of translational advancement signals from the 2008–2023 dataset. No approved products or phase II/III readouts were identified for ncRNA, modRNA, or Hippo-targeted agents.
Track Cardiac Regeneration IP Opportunities with PatSnap Eureka
Identify white-space in Hippo pathway modulators, cardiac-specific AAV delivery, and modRNA manufacturing for cardiac indications.
What This Pipeline Means for Drug Developers & IP Teams
modRNA platform differentiation: The retrieved modRNA results (Myc-Ccnt1, FSTL1-N180Q) position modified mRNA as a compelling delivery modality for transient pro-proliferative cargo in cardiac indications. The transient, non-integrating profile addresses key safety concerns that have historically limited gene therapy approaches in cardiology. Developers with existing mRNA manufacturing infrastructure are well positioned to advance this application.
YAP/Hippo pathway is a high-conviction target with validated small molecule entry points: TT-10 demonstrates that pharmacological YAP/TEAD activation in vivo improves post-MI function in mice. The convergence of independent research groups (MD Anderson, Kansai Medical University, UT Southwestern) on Hippo/YAP as a regenerative effector supports prioritising this axis for lead optimisation and IP protection, particularly given the absence of patent filings in the retrieved dataset for cardiac-specific Hippo modulators. The PatSnap analytics platform can surface this white space systematically.
ncRNA therapeutic development is predominantly academic and preclinical: Despite the large volume of ncRNA-focused retrieved literature, translational advancement is constrained by delivery challenges (tropism, stability, off-target effects). IP development around cardiac-specific ncRNA delivery vehicles (AAV serotypes, lipid nanoparticles) may represent an underexplored IP opportunity. The EPO and WIPO patent databases, accessible through PatSnap Eureka, can reveal the true filing landscape.
Combination strategies are the likely path to clinical efficacy: No single retrieved approach produces complete cardiac regeneration. The convergence of signals around combination strategies (small molecule + ncRNA, reprogramming factor + cell cycle activator, anti-fibrotic + pro-proliferative) suggests future clinical programs will require multi-modal product designs — with corresponding complexity in IP composition-of-matter claims, manufacturing, and regulatory classification. Explore how leading life sciences teams use PatSnap for life sciences R&D intelligence.
Cardiac Regeneration Drug Pipeline — key questions answered
Adult mammalian cardiomyocytes exit the cell cycle perinatally and enter a postmitotic state that prevents meaningful endogenous regeneration. Following myocardial infarction, the irreversible loss of cardiomyocytes drives progression to heart failure because the adult heart cannot adequately repair itself.
The Hippo pathway operates through MST1/2 and LATS1/2 kinases that phosphorylate and inactivate the transcriptional co-activator YAP; when Hippo signaling is suppressed, YAP enters the nucleus and drives pro-proliferative gene programs. Therapeutic strategies center on either inhibiting upstream kinases or delivering constitutively active YAP. The small molecule TT-10 activates YAP/TEAD in cardiomyocytes in vivo with functional benefit post-MI.
modRNA strategies use non-integrating modified mRNA to transiently express pro-proliferative cargo in cardiomyocytes. Two key examples are: Myc-Ccnt1 modRNA (University of Queensland, 2023), where a single dose drove cardiomyocyte proliferation in human iPSC-derived CMs and a mouse MI model; and FSTL1 modRNA (Icahn School of Medicine at Mount Sinai, 2018), which used a glycosylation-site mutant to induce cardiomyocyte proliferation. The transient, non-integrating nature addresses key safety concerns for clinical translation.
Pro-proliferative miRNAs include miR-590, miR-199a, miR-17-92 cluster, miR-302-367 cluster, and miR-222. Anti-proliferative miRNAs include miR-1 and miR-133. The miR-106b~25 cluster orchestrates the transition from cardiomyocyte hyperplasia to hypertrophy. lncRNA Snhg1 forms a positive feedback loop with c-Myc via PI3K-AKT to induce stable cardiomyocyte cytokinesis. Exercise-induced miR-222 was identified as a required mediator of cardiomyocyte birth following 8 weeks of running exercise, producing approximately a 4.6-fold increase in new cardiomyocytes in adult mice.
Key small molecules include: CHIR99021 (GSK-3β inhibitor), shown to promote cardiomyocyte proliferation in human iPSC-derived CMs in 3D collagen microtissues; CHIR99021 combined with A-485 (2C combination) to generate regenerative cardiac cells from hESC-derived CMs; Cyclin D2 overexpression producing more than 500-fold increase in cell cycle activity and infarct regression in postnatal mouse hearts; and TT-10, a small molecule YAP/TEAD activator that reduces post-MI cardiac dysfunction in mice via clonal expansion of existing cardiomyocytes.
Clinical translation signals are limited but present. AAV9-mediated cardiac delivery of miR-301a in mouse MI models is identified as a translational delivery strategy. Both Myc-Ccnt1 and FSTL1 modRNA studies explicitly frame their approaches as translational due to transient expression and lack of genomic integration. Several retrieved results reference clinical trials using bone marrow-derived stem cells and cardiac progenitor cells with generally inconsistent or modest outcomes. Retrieved results do not contain direct references to regulatory submissions, approved products for cardiomyocyte proliferation indications, or phase II/III trial readouts for any ncRNA, modRNA, or Hippo-targeted agent.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About This PipelineAccelerate Your Cardiac Regeneration Research with AI-Powered Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map drug pipelines, identify IP white space, and track emerging therapeutic targets in cardiovascular disease.
References
- Non-coding RNAs to regulate cardiomyocyte proliferation: A new trend in therapeutic cardiac regeneration — Second Xiangya Hospital, Central South University (2022)
- The Hippo Pathway in Cardiac Regeneration and Homeostasis: New Perspectives for Cell-Free Therapy in the Injured Heart — MD Anderson Cancer Center / UTHealth (2020)
- The molecules and mechanisms of heart development, disease and regeneration — King Abdulaziz University / UT Southwestern (2014)
- LncRNA Snhg1-driven self-reinforcing regulatory network promotes cardiomyocyte cytokinesis — Nanfang Hospital, Southern Medical University (2020)
- LncRNA Snhg1-driven self-reinforcing regulatory network promoted cardiac regeneration after myocardial infarction — Nanfang Hospital, Southern Medical University (2021)
- Exercise induces new cardiomyocyte generation in the adult mammalian heart — Harvard Medical School (2018)
- miR-301a-PTEN-AKT Signaling Induces Cardiomyocyte Proliferation and Promotes Cardiac Repair Post-MI — Shanghai East Hospital, Tongji University (2020)
- A microRNA program regulates the balance between cardiomyocyte hyperplasia and hypertrophy — ICGEB, Trieste (2021)
- A microRNA program controls the transition of cardiomyocyte hyperplasia to hypertrophy — Maastricht University (2021)
- A transient modified mRNA encoding Myc and Cyclin T1 induces cardiac regeneration and improves cardiac function after myocardial injury — University of Queensland (2023)
- Ablation of a Single N-Glycosylation Site in Human FSTL1 Induces Cardiomyocyte Proliferation and Cardiac Regeneration — Icahn School of Medicine at Mount Sinai (2018)
- Discovery of a Small Molecule to Increase Cardiomyocytes and Protect the Heart After Ischemic Injury (TT-10) — Kansai Medical University (2018)
- CHIR99021 Promotes hiPSC-Derived Cardiomyocyte Proliferation in Engineered 3D Microtissues — Friedrich-Alexander University Erlangen-Nürnberg (2021)
- Pharmacologically inducing regenerative cardiac cells by small molecule drugs — Tsinghua University (2023)
- Single-cell analysis uncovers that metabolic reprogramming by ErbB2 signaling is essential for cardiomyocyte proliferation — Vrije Universiteit Amsterdam (2019)
- Amino acid primed mTOR activity is essential for heart regeneration — University of Washington (2022)
- Nrg1 is an injury-induced cardiomyocyte mitogen for the endogenous heart regeneration program in zebrafish — Duke University (2015)
- OSKM-mediated reversible reprogramming of cardiomyocytes regenerates injured myocardium — University of North Carolina (2022)
- Inhibition of the NOTCH1 Pathway in the Stressed Heart Limits Fibrosis — University of Lausanne (2022)
- World Health Organization — Cardiovascular Diseases Fact Sheet
- WIPO — Global Patent Database
- European Patent Office — Espacenet Patent Search
- National Institutes of Health — mRNA Therapeutics Research
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.